Albireo Pharma

$36.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.14 (-3.06%) As of 8:50 PM UTC today

Why Robinhood?

You can buy or sell Albireo Pharma and other stocks, options, and ETFs commission-free!

About ALBO

Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. The listed name for ALBO is Albireo Pharma, Inc. Common Stock.

CEO
Ronald H. W. Cooper
Employees
55
Headquarters
Boston, Massachusetts
Founded
2003
Market Cap
722.14M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
207.12K
High Today
$37.80
Low Today
$35.88
Open Price
$37.20
Volume
129.59K
52 Week High
$49.00
52 Week Low
$11.26

ALBO Earnings

-$2.23
-$1.68
-$1.12
-$0.57
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.94 per share
Actual
-$1.30 per share
Replay Earnings Call

You May Also Like

ADI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure